Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchiolitis Obliterans Syndrome Clear all
Completed Phase 1Phase 2 Interventional Results available

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 3, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

NCT06695507
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain (Phase 2)

NCT02986334
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Omeprazole, Placebo
Drug
Lead sponsor
Apkar Apkarian
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

NCT00391820
View directory record Official record
Conditions
Chronic Constipation
Interventions
TD-5108
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years to 64 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Not applicable Interventional

Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)

NCT00521196
View directory record Official record
Conditions
Migraine
Interventions
DC Stimulator (Transcranial Direct Current Stimulator)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Not applicable Interventional

Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits

NCT06288217
View directory record Official record
Conditions
Upper Extremity Paresis, Stroke, Chronic
Interventions
NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation), Upper Limb Rehabilitation, Sham Stimulation
Device · Other
Lead sponsor
NeuraStasis, Inc
Industry
Eligibility
30 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 3, 2026, 4:04 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT03584516
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Itacitinib, Placebo, Methylprednisolone, Prednisone
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 3, 2026, 4:04 PM EDT
Recruiting Phase 1 Interventional

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

NCT06462365
View directory record Official record
Conditions
Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic, Hematopoietic Stem Cell Transplant, Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, Adult T-Cell, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, in Remission, Cancer Remission
Interventions
TRX103
Biological
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Not applicable Interventional

ED Physical Therapy for Chronic Low Back Pain

NCT05206630
View directory record Official record
Conditions
Low Back Pain
Interventions
ED Physical Therapy
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab for Prevention of Chronic GVHD

NCT00379587
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Rituximab, 375 mg/m2 RRituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)

NCT01161628
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Rituximab
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children

NCT00144430
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pentostatin
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Month to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
25
States / cities
Loma Linda, California • Oakland, California • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Oct 3, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional Results available

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01163253
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 3, 2026, 4:04 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury

NCT06841770
View directory record Official record
Conditions
Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Acute, Spinal Cord Injury, Spinal Cord Injury, Chronic
Interventions
OPC1
Biological
Lead sponsor
Lineage Cell Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
2
States / cities
Downey, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

NCT02959944
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
ibrutinib, Placebo, Prednisone
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
12 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
38
States / cities
Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 3, 2026, 4:04 PM EDT
Terminated Phase 1Phase 2 Interventional

Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG

NCT01815346
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Questionnaires, Hand Function and Balance Tests
Procedure · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 3, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional Results available

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

NCT02337517
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Laboratory Biomarker Analysis, Vismodegib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Ann Arbor, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 3, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant

NCT04239989
View directory record Official record
Conditions
Bronchiolitis Obliterans
Interventions
Itacitinib, Itacitinib Adipate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 3, 2026, 4:04 PM EDT
Withdrawn Early Phase 1 Interventional

Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence

NCT03845322
View directory record Official record
Conditions
Hematoma, Subdural, Chronic
Interventions
Curcumin Pill, Placebo pills
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Targeted Therapy of Bronchiolitis Obliterans Syndrome

NCT01307462
View directory record Official record
Conditions
Bronchiolitis Obliterans
Interventions
fluticasone propionate, montelukast sodium, azithromycin
Drug
Lead sponsor
Stephanie Lee
Other
Eligibility
6 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Scottsdale, Arizona • Stanford, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 3, 2026, 4:04 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

NCT06233110
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Fostamatinib, Ruxolitinib
Drug
Lead sponsor
Stefanie Sarantopoulos, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 3, 2026, 4:04 PM EDT
Withdrawn Phase 1 Interventional

Regulating Urine pH Levels to Alleviate Chronic Joint Pain

NCT01421160
View directory record Official record
Conditions
Arthritis
Interventions
sodium citrate and citric acid
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 3, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

NCT04063215
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 3, 2026, 4:04 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sub-Sensory Intraspinal Neurostimulation Therapy

NCT01976598
View directory record Official record
Conditions
Back Pain, Back Pain With Radiation, Pain in Leg, Unspecified
Interventions
Sub-Sensory Stimulation
Other
Lead sponsor
Algos Clinical Development Thomas L. Yearwood, MD, PhD
Other
Eligibility
22 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pascagoula, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 3, 2026, 4:04 PM EDT